Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: Nationwide cohort and nested case-control study

BMJ (Online)

Volumn 353, Issue , 2016, Pages

  Abrahamsen, Bo ^a,b   Eiken, Pia ^c,d   Prieto Alhambra, Daniel ^e,f   Eastell, Richard ^g  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b HOLBÆK HOSPITAL   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; PREDNISOLONE; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DENMARK; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MIDDLE AGED; ODDS RATIO; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; FEMALE; FEMORAL FRACTURES; LONG TERM ADVERSE EFFECTS; MALE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; DENMARK; FEMALE; FEMORAL FRACTURES; HUMANS; INCIDENCE; LONG TERM ADVERSE EFFECTS; MALE; MIDDLE AGED; ODDS RATIO; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 84977121542     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i3365     Document Type: Article

References (35)

1. Russell RG. Bisphosphonates: the first 40 years. Bone 2011;49:2-19. doi:10.1016/j.bone.2011.04.022.
2. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29:1-23. doi:10.1002/jbmr.1998.
3. Järvinen TL, Michaëlsson K, Aspenberg P, Sievänen H. Osteoporosis: the emperor has no clothes. J Intern Med 2015;277:662-73. doi:10.1111/joim.12366.
4. Jha S, Wang Z, Laucis N, Bhattacharyya T. Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis. J Bone Miner Res 2015;30:2179-87. doi:10.1002/jbmr.2565.
5. Svedbom A, Hernlund E, Ivergård M, et al. EU Review Panel of IOF. Osteoporosis in the European Union: a compendium of countryspecific reports. Arch Osteoporos 2013;8:137. doi:10.1007/s11657-013-0137-0.
6. Järvinen TL, Michaëlsson K, Jokihaara J, et al. Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ 2015;350:h2088. doi:10.1136/bmj.h2088.
7. Black DM, Schwartz AV, Ensrud KE, et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38. doi:10.1001/jama.296.24.2927.
8. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015;30:934-44. doi:10.1002/jbmr.2442.
9. Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B. Risks and Benefits of Bisphosphonate Therapies. J Cell Biochem 2016;117:20-8. doi:10.1002/jcb.25266.
10. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 2015;86:100-7. doi:10.3109/17453674.2015.1004149.
11. Wang Z, Ward MM, Chan L, Bhattacharyya T. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries. Osteoporos Int 2014;25:2109-16. doi:10.1007/s00198-014-2738-x.
12. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010;95:5258-65. doi:10.1210/jc.2010-1571.
13. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, Schmidt M, Pedersen L, Sørensen HT. Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin Epidemiol 2012;4:303-13. doi:10.2147/CLEP. S37587.
14. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9. doi:10.1097/01.mlr.0000182534.19832.83.
15. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22. doi:10.4065/81.8.1013.
16. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8. doi:10.1007/s00198-004-1652-z.
17. Selga J, Nuñez JH, Minguell J, Lalanza M, Garrido M. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporos Int 2016;27:827-32. doi:10.1007/s00198-015-3355-z.
18. Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 2013;52:360-5. doi:10.1016/j.bone.2012.10.006.
19. Chatellier G, Zapletal E, Lemaitre D, Menard J, Degoulet P. The number needed to treat: a clinically useful nomogram in its proper context. BMJ 1996;312:426-9. doi:10.1136/bmj.312.7028.426.
20. Lalmohamed A, Vestergaard P, Klop C, et al. Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. Arch Intern Med 2012;172:1229-35. doi:10.1001/archinternmed.2012.2713.
21. Taormina DP, Marcano AI, Karia R, Egol KA, Tejwani NC. Symptomatic atypical femoral fractures are related to underlying hip geometry. Bone 2014;63:1-6. doi:10.1016/j.bone.2014.02.006.
22. Saita Y, Ishijima M, Mogami A, et al. The fracture sites of atypical femoral fractures are associated with the weight-bearing lower limb alignment. Bone 2014;66:105-10. doi:10.1016/j.bone.2014.06.008.
23. Schilcher J, Howe TS, Png MA, Aspenberg P, Koh JS. Atypical Fractures are Mainly Subtrochanteric in Singapore and Diaphyseal in Sweden: A Cross-Sectional Study. J Bone Miner Res 2015;30:2127-32. doi:10.1002/jbmr.2547.
24. Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011;48:966-71. doi:10.1016/j.bone.2010.12.033.
25. Muschitz C, Thaler HW, Dimai HP, et al. Atypical Femoral Fractures-Ongoing and History of Bone-Specific Therapy, Concomitant Diseases, Medications, and Survival. J Clin Densitom 2015;S1094-6950(15)00126-2.
26. Napoli N, Schwartz AV, Palermo L, et al. Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures. J Clin Endocrinol Metab 2013;98:659-67. doi:10.1210/jc.2012-1896.
27. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012;27:2544-50. doi:10.1002/jbmr.1719.
28. Feldstein AC, Black D, Perrin N, et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012;27:977-86. doi:10.1002/jbmr.1550.
29. Kharazmi M, Hallberg P, Schilcher J, Aspenberg P, Michaëlsson K. Mortality After Atypical Femoral Fractures: A Cohort Study. J Bone Miner Res 2016;31:491-7. doi:10.1002/jbmr.2767.
30. Abrahamsen B, Prieto-Alhambra D. Patients With Atypical Femur Fractures Have the Same Mortality as the Background Population-Drug-Channeling Bias, Bisphosphonate Effects, and Public Health Implications. J Bone Miner Res 2016;31:488-90. doi:10.1002/jbmr.2801.
31. Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008;23:1569-75. doi:10.1359/jbmr.080510.
32. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;(1):CD001155.
33. Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010;362:1848-9. doi:10.1056/NEJMc0910389.
34. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37. doi:10.1056/NEJMoa1010650.
35. Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012;172:930-6. doi:10.1001/archinternmed.2012.1796.